KCT0008805尚未招募Unknown
Multimodal imaging study using Florzolotau PET and brain MRI for the patients with frontotemporal lobar degeneration and atypical Parkinsonism
试验速览
- 阶段
- Unknown
- 状态
- 尚未招募
- 入组人数
- 120
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Observational
入排标准
- 年龄范围
- 20(Year) 至 85(Year)（—）
- 性别
- All
入选标准
- •Patient Group: Patients who visited the neurology department at GMC (Patients should be adults, aged 20 or older, and meet the following conditions for research enrollment)
- •-Frontotemporal dementia (FTD)
- •Probable FTD patients according to the revised guidelines for the diagnosis of behavioral variant FTD by the international consortium (2011),
- •-Atypical parkinsonism
- •Probable progressive supranuclear palsy (PSP) patients according to the Movement Disorder Society Criteria for the clinical diagnosis of PSP (2017).
- •Probable corticobasal degeneration (CBD) patients according to the criteria for the diagnosis of CBD (2013).
- •Normal Control Group
- •: Normal individuals who do not have neurologic or psychiatric diseases and have normal cognitive function (n=30)
- •-People aged 40-85 years old who have agreed to participate in the study and have no neurological or psychiatric disorders.
- •-Participant without a family history of dementia, Parkinson's disease, or schizophrenia.
- •-Participant with normal cognitive function according to neuropsychological tests.
- •-Participant who does not meet any other exclusion criteria.
排除标准
- •1) The following individuals are excluded from the patient group selection process:
- •-Pregnant women (those who are suspected of being pregnant at all are excluded from the study subjects by identifying pregnancy status and the date of the last menstrual period through a survey).
- •-Women who are currently breastfeeding
- •-Patients whose overall physical condition is so poor that it is difficult to perform the examination.
- •-People with seizure symptoms such as claustrophobia or other epilepsy
- •-Patients who have had a large-sized stroke in the brain, brainstem, or cerebellum
- •-Patients with brain tumors, varicella, encephalitis, metabolic brain diseases
- •-Women who are pregnant or have an intrauterine contraceptive device
- •-Individuals who are deemed inappropriate by clinical trial researchers for reasons other than the above items
- •-Individuals with a cardiac pacemaker or metallic material inserted into the body (except for those who have titanium or titanium alloys implanted/transplanted and those who have been confirmed by a specialist to have no problem with a 3T MRI scan).
- •2) The following individuals are excluded from the normal control group selection process:
- •-Pregnant women (those who are suspected of being pregnant at all are excluded from the study subjects by identifying pregnancy status and the date of the last menstrual period through a survey).
- •-Women who are currently breastfeeding
- •-Researchers or students within the research institution who are deemed difficult to voluntarily participant
- •-Patients whose overall physical condition is so poor that it is difficult to perform the examination.
- •-Individuals with serious psychiatric problems
- •-People with central nervous system diseases or sequelae of previous neurological disorders affecting cognitive function
- •-People with abnormal findings on past brain MRI or PET scans
- •-People with seizure symptoms such as claustrophobia or other epilepsy
- •-Patients with brain diseases.
研究者
相似试验
终止
2 期
[18F]Fluciclatide PET Imaging of Pazopanib ResponseKidney NeoplasmNCT01961583Asan Medical Center12
已完成
不适用
F-18-Fluorocholine PET/CT and MR Imaging/ Spectroscopy in the Management of Primary and Recurrent Prostate CancerProstate CancerNCT00963755University of Lausanne Hospitals60
Unknown
早期 1 期
IRDye800CW-BBN PET-NIRF Imaging Guiding Surgery in Patients With GlioblastomaGlioblastomaNCT02910804Beijing Tiantan Hospital30
进行中（未招募）
1 期
Combined 64Cu-DOTATATE and 18F-FDG PET/CT Imaging in Patients with Neuroendocrine Tumorseuroendocrine neoplasmsMedDRA version: 21.0Level: LLTClassification code 10062476Term: Neuroendocrine tumorSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)MedDRA version: 20.0Level: PTClassification code 10057270Term: Neuroendocrine carcinomaSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)MedDRA version: 21.0Level: LLTClassification code 10068916Term: Pancreatic neuroendocrine tumor metastaticSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)MedDRA version: 20.0Level: PTClassification code 10071542Term: Neuroendocrine carcinoma metastaticSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)MedDRA version: 20.0Level: LLTClassification code 10077560Term: Gastroenteropancreatic neuroendocrine tumor diseaseSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)MedDRA version: 21.0Level: LLTClassification code 10067518Term: Pancreatic neuroendocrine tumorSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)MedDRA version: 24.1Level: LLTClassification code 10085846Term: Duodenal neuroendocrine tumorSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)MedDRA version: 24.1Level: LLTClassification code 10085958Term: Small intestine neuroendocrine tumorSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)EUCTR2021-005919-30-DKDepartment of Clinical Physiology and Nuclear Medicine, Rigshospitalet200
已完成
1 期
Flortaucipir PET Imaging in Subjects With FTDFrontotemporal DementiaNCT03040713Avid Radiopharmaceuticals16